Background. Evidence on the effectiveness of first-line treatment for chronic Q fever, tetracyclines (TET) plus hydroxychloroquine (HCQ), and potential alternatives is scarce.
Chronic Q fever is a zoonosis caused by the intracellular coccobacillus Coxiella burnetii [1, 2] . Shortly after discovery of C. burnetii, it was found that penicillin was not beneficial as treatment for Q fever, which is in contrast to tetracyclines (TET) [3] . In the 1950s, Q fever endocarditis was first recognized [4, 5] . It was presumed that there was no definitive treatment and that suppression was achieved with TET and chloramphenicol [5] .
In the 1990s, treatment of chronic infection with TET plus quinolones (QNL) was found to be more effective than treatment with TET alone [6] . Later, it was hypothesized that TET would be more effective combined with an alkalizing agent such as hydroxychloroquine (HCQ) since C. burnetii replicates within macrophages and monocytes where the acidified phagosomal compartment decreases the bactericidal efficacy of antibiotics [7] .
TET plus HCQ was indeed found to be superior to TET plus QNL in terms of relapse and treatment duration in a retrospective study of 35 patients [8] . However, evidence on superiority of TET plus HCQ compared to other regimens is limited and inconsistent. In a study of 30 patients with vascular chronic Q fever, TET plus HCQ was not superior to TET plus QNL or TET alone in reducing mortality [9] . It is currently advised to treat chronic Q fever patients with TET plus HCQ; TET plus QNL is considered a potential alternative [8] .
All available evidence on optimal treatment has been derived from small, observational studies [7] [8] [9] . Both TET and HCQ may cause significant toxicity such as photosensitivity, retinopathy, and black hyperpigmentation [10, 11] . Therefore, additional evidence on treatment options for chronic Q fever is needed.
Since chronic Q fever is rare, it is difficult to identify the optimal antibiotic treatment regimen as it relates to mortality, morbidity, and side effects. After a large Q fever outbreak in the Netherlands (2007) (2008) (2009) (2010) [12] , we identified all known patients with chronic Q fever and evaluated effectiveness of different treatment strategies.
METHODS

Data Collection
We used data from the Dutch national chronic Q fever database where clinical, microbiological, and imaging data of all known chronic Q fever patients in the Netherlands are stored. Registration started in February 2011 and the last update ended in May 2016. Data collection within this cohort was approved by the medical ethical committee of the University Medical Centre in Utrecht, the Netherlands. All Dutch hospitals with microbiological laboratories were approached and asked to participate; 28 hospitals participated, and all but 1 hospital in the Q fever epidemic area participated.
Patient Inclusion
Patients aged ≥18 years at the time of data collection with proven or probable chronic Q fever according to the definitions formulated by the Dutch chronic Q fever consensus group were included [13] . In the Netherlands, all patients are categorized according to these criteria after a national guideline on diagnosis of chronic Q fever was published [14] . The criteria overlap substantially with the criteria formulated by Eldin et al, except for the fact that classification depends on likelihood of infection instead of focus of infection [13, 15] . Diagnostic classification was reviewed in all patients by 4 investigators (C. B., P. W., J. J. O., and S. R.). Possible chronic Q fever patients were not evaluated since infection is not established in these patients and there is no indication for treatment. Microbiologists identified patients based on a positive polymerase chain reaction (PCR) on serum or tissue and/or C. burnetii phase I immunoglobulin (Ig) G antibodies ≥1:1024 in serum. Patients with a serological profile and clinical condition that matched acute Q fever were excluded. Antibody titers were analyzed using indirect fluorescent-antibody assay for phase I and II IgG against C. burnetii on plasma or serum (Focus Diagnostics, Inc., Cypress, California, or Fuller Diagnostics, LLC, Anchorage, Alaska). Titration of antibody levels was carried out at different hospital sites with dilutions on a binary scale with a cutoff of 1:32. Results of PCR for C. burnetii DNA on serum or plasma were collected and, if applicable, on tissue samples (NucliSENS easyMAG; bioMérieux, Marcy l'Etoile, France).
Treatment Regimens
Clinicians treated their patients based on national guidelines, local guidelines, literature, or their own experience. The Dutch national guideline advises doxycycline (200 mg once daily) plus HCQ (200 mg 3 times daily) and suggests potential alternatives (either QNL, rifampicin, or co-trimoxazole combined with doxycycline) [16] . We categorized and analyzed TET plus HCQ (reference category), TET plus QNL, TET plus QNL plus HCQ, TET monotherapy, and QNL monotherapy. Despite the overlap between TET plus QNL plus HCQ and TET with only HCQ or QNL, we analyzed this group separately because this treatment regimen is significantly more intensive. Antibiotics that did not belong to any of these categories were integrated in the model as "other antibiotics" and reported. Single antibiotics used in addition to the above regimens were reported but not analyzed separately. The end of the observation period was defined as 1 May 2016. Thus, for patients who were being treated at the end of the data collection period, treatment duration was calculated until 1 May 2016.
Outcome and Complications
The primary outcome of this study was all-cause mortality. Secondary outcomes were first disease-related event during treatment (new complication or chronic Q fever-related mortality) and therapy failure (new complication during treatment or a new positive PCR having been negative for at least 3 months or a persistent positive PCR for more than 6 months or chronic Q fever-related mortality). All-cause mortality was chosen as the primary outcome since this is the only endpoint not subject to subjectivity.
Conditions that were considered to be complications of chronic Q fever were rupture or dissection of aneurysm, acute symptomatic aneurysm, arterial fistula, endoleak of vascular prosthesis, spondyl(odisc)itis or osteomyelitis, (cardiac) abscess, cerebrovascular accident (hemorrhagic or ischemic)/ transient ischemic attack, and cardiac arrest or tamponade during pericarditis. Definitions of complications were based on complications that occurred during intravascular infections reported in the literature [17] [18] [19] [20] [21] .
Causes of death were reviewed by 2 investigators (C. P. B. R. and S. E. v. R.); classification of the relationship between death and chronic Q fever was performed by reaching consensus. Cause of death was defined as definitely or probably related to chronic Q fever in case of active disease and cause of death potentially related to chronic Q fever. Active disease was defined as C. burnetii phase I IgG ≥1:1024 or positive PCR on serum or tissue. Causes of death potentially related to chronic Q fever were defined as sepsis/feverish episode with no other cause, brain infarct or hemorrhage during endocarditis or due to cerebral aneurysm, arterial fistula, ruptured/dissected aneurysm, heart failure, fatal arrhythmia or cardiac arrest during endocarditis, surgical complications, side effects of antibiotic therapy, clinical deterioration during active disease with no other cause, Q fever as cause of death proven by autopsy, and unknown cause in the presence of Q fever-related complications or unknown cause without adequate Q fever treatment. PCR relapse was defined as a newly positive PCR after stopping treatment.
Statistical Methods
Categorical data were compared using the Fischer exact test or χ 2 as appropriate. Continuous variables were compared using the independent samples t test or Mann-Whitney U test as appropriate.
To compare the effect of different antibiotics for chronic Q fever on the occurrence of primary and secondary outcomes, we used a Cox proportional hazards model with the determinant (antibiotics for chronic Q fever) incorporated as the categorical time-varying covariate. A time-varying covariate allows the study of multiple consecutive treatment regimens among patients over time. The currently advised first-line treatment, TET plus HCQ, was set as the reference category.
Propensity scores were integrated into the model to adjust for heterogeneity in prognosis and potential confounders. Variables were selected based on prior studies that explored which factors predict adverse outcomes in patients with chronic Q fever (van Roeden, manuscript in preparation). Additionally, surgical interventions and comorbidities that influence prognosis were included. In the propensity score for overall mortality, age, gender, immunocompromised state, presence of prosthetic material prior to chronic Q fever diagnosis, focus of infection, PCR positivity, use of statins or platelet aggregation inhibitors, surgical intervention, preexisting heart failure or renal insufficiency, smoking, diagnostic classification, and time to start antibiotics after diagnosis were included. In the propensity score for the first disease-related events, equal variables were included with the exception of surgical intervention since this may be an intermediate variable. In the propensity score for therapy failure, equal variables were included again with the exception of surgical intervention and with the exception of PCR positivity since this is incorporated in the outcome.
For combined endpoints, we specifically studied the first event since consecutive events per patient are not independent. We calculated cause-specific hazards for all-cause mortality and subdistribution hazards for combined endpoints (first disease-related event and therapy failure) in order to optimally account for competing risks. In chronic Q fever, there is a delay between start of antibiotics and clinical effect. Therefore, the models were fit with different "lagged times" for treatment (0, 2, and 4 weeks). The model with the lowest Akaike's information (16) 40 (16) 10 (14) Diabetes mellitus (%) 46 (14) 32 (13) 14 (19) Presence of prosthetic material prior to complication (%) 166 (52) 142 ( Immunocompromised state: 39 patients using immunosuppressives (usage of >5 mg prednisone daily >30 days or cumulative dosage exceeding 750 mg, azathioprine, methotrexate, tumor necrosis factor-α blockers, mycophenolic acid, cyclosporine, sulfasalazine or a combination of these),1 patient with chemotherapy for nonhematological malignancy, 5 patients with hematological malignancies with cytopenia or requiring treatment (hairy cell leukemia, myelodysplastic syndrome, chronic lymphatic leukemia, and non-Hodgkin lymphoma), 4 patients post-splenectomy, and 2 patients with immunoglobulin G deficiency/common variable immunodeficiency. Three patients fulfill 2 categories: all 3 with hematological malignancies (2 with immunosuppressive medication for other diseases and 1 post-splenectomy). c Not applicable in 23 patients.
criterion was selected for analysis. This model had a lag time of 4 weeks. Longer lag times were considered to be unrealistic based on advice of experienced clinicians. Sensitivity analyses for the most nearby lag times (2 and 6 weeks) were performed to ensure robustness of the data. Potential left-censoring was accounted for by stratification for the presence of complications before the start of treatment.
To correct for clustering of patients within the same hospital and differences between hospitals, a random effect for hospital was included by fitting shared-frailty terms in the model (assuming a Gaussian distribution of the frailty parameter).
The Cox regression models were fit with the "cmprsk" and "survival" packages in R studio, version 3.2.2 [22] . The proportional hazard assumption was verified and confirmed both with formal tests and graphically using Schoenfeld residuals. Descriptive data were generated with SPSS, version 21.0.
Missing Data
For 1 patient, all data regarding covariates, exposure, and outcome were missing. This patient was excluded from analysis. In all other patients, data regarding exposure and outcome were complete. Missing data on covariates, baseline characteristics, or side effects were described beneath concerning tables. In the Cox regression analysis, missing data on covariates were included as separate categories in the analysis since it is unlikely that these data are missing at random.
RESULTS
We identified 439 chronic Q fever patients. One patient was excluded because detailed data on treatment of this patient were missing, and 116 patients were excluded because they had possible chronic Q fever. Of 322 remaining patients, 248 (77%) patients had proven chronic Q fever and 74 (23%) probable chronic Q fever. Baseline characteristics are shown in Table 1 .
Overview of Therapy
Overall, 276 (86%) patients were treated with antibiotics. TET plus HCQ was most frequently prescribed (n = 254; 92%); 232 (84%) patients started with TET plus HCQ. A complete overview of antibiotic treatment regimens is presented in Table 2 . Treatment was deescalated from a Median total duration, wk (IQR) 37 (10-98) 37 (13-100) 4 (3-77)
TET prescribed: doxycycline for 267 patients, minocycline for 5 patients. QNL prescribed: moxifloxacin for 104 patients, ciprofloxacin for 58 patients, ofloxacin for 1 patient (multiple TET or QNL within 1 individual possible); 100% of patients on doxycycline started on standard dosage (200 mg daily), dosage was adjusted later on in 29%; 95% of patients on HCQ started on standard dosage (600 mg daily), dosage was adjusted later on in 22%. Ciprofloxacin was started in an alternative dosage in 43% of patients (adjusted on renal function), dosage was adjusted later on in 16%. Moxifloxacin was started on standard dosage in 99% of patients, dosage was adjusted later on in 2% of patients.
Abbreviations: HCQ, hydroxychloroquine; IQR, interquartile range; QNL, quinolone; TET, tetracycline. a Percentage of patients receiving treatment.
b Of those finished, 185 were treated with TET plus HCQ, 34 with TET plus QNL, 13 with TET plus QNL plus HCQ (some patients used multiple combinations).
c Simultaneous use of other (combination of) antibiotics >1 month in 7 patients (4 co-trimoxazole, 1 clindamycin, 3 rifampicin, 1 clarithromycin).
d Simultaneous use of (combination of) other antibiotics >1 month in 2 patients (2 rifampicin).
e Simulataneous use of (combination of) other antibiotics >1 month in 2 patients (1 rifampicin, 1 clindamycin, 1 co-trimoxazole).
f Simultaneous use of (combination of) other antibiotics >1 month in 19 patients (10 rifampicin, 6 hydroxychloroquine, 2 co-trimoxazole, 1 clarithromycin). doxycycline with other than QNL or HCQ (7 rifampicin, 2 chloroquine, 2 co-trimoxazole, 1 clarithromycin, 1 rifampicin/co-trimoxazole, 1 rifampicin/clarithromycin).
combination of antibiotics to single antibiotics in 64 patients (23%), intensified (from monotherapy to combination therapy) in 12 patients (4%), both deescalated and intensified in 56 patients (20%) and neither deescalated or intensified in the remaining 144 patients (52%). Reasons for withholding treatment from patients with proven chronic Q fever were refusal (n = 4), death before start of treatment (n = 7), chronic Q fever not recognized by the clinician (n = 6), and unknown (n = 4). Reasons for withholding treatment from patients with probable chronic Q fever were refusal (n = 4), chronic Q fever not recognized by the clinician (n = 4), clinician doubted the diagnosis (n = 6), and unknown (n = 11).
Clinical Outcomes
Numbers of events occurring during different antibiotics regimens are shown in Table 3 (Table 3) . Sensitivity analyses for the most nearby lag times (2 and 6 weeks) did not change the HRs significantly. None of the outcomes were associated with de-escalation or intensifying treatment in univariable analysis.
Antibiotic Changes and Discontinuation
Multiple consecutive antibiotic regimes were used by 161 (58%) patients (Supplementary Figure S1) . TET plus HCQ was most frequently discontinued due to side effects (n = 110; 43%), followed by TET plus QNL plus HCQ (n = 12; 41%). TET monotherapy and QNL monotherapy were most often discontinued due to insufficient clinical response (n = 32; 59% and n = 27; 29%; see Table 4 ).
Side Effects
Side effects were most frequently observed during treatment with TET plus QNL plus HCQ (n = 24; 83%), TET plus QNL (n = 40; 82%), and TET plus HCQ (n = 190; 75%). Severity of side effects is described in Table 4 . In 3 patients treated with TET plus HCQ, side effects were considered potentially fatal (n = 3; 1%); all 3 cases were due to severe dehydration based on gastrointestinal side effects. Most frequently reported side effects were gastrointestinal complaints and photosensitivity.
Course of Disease After Stopping Treatment
In total, 161 patients finished antibiotic treatment before the end of the study (not because of death) or paused antibiotic treatment at some point. Thus, 161 patients were at risk for PCR-positive relapse or chronic Q fever-related mortality after stopping treatment (Table 5) . We observed 5 patients (3%) with PCR-positive relapse and 16 chronic Q feverrelated deaths (10%) after stopping antibiotics. Patients who Abbreviations: HCQ, hydroxychloroquine; HR, hazard ratio; QNL, quinolone; SHR, subdistribution hazard ratio; TET, tetracycline. a Significant covariate: therapy exposure category "treatment finished" (HR, 0·36; 95% confidence interval [CI], 0·18 -0·75; P < ·01) and propensity score (HR, 18.74 per point increase; 95% CI, 7.54 -46.55; P < .01). Mean propensity score deceased 0.48; mean propensity score nondeceased 0.26. b Significant covariate: therapy exposure category "treatment finished" (HR, 0·40; 95% CI, 0·20 -0·80; P < ·01) and propensity score (HR,12.32 per point increase; 95% CI, 5.01 -30.30; P < .01). Mean propensity score with event 0.53; mean propensity score without event 0.30. c Significant covariate: therapy exposure category "treatment finished" (HR, 0·32; 95% CI, 0·17 -0·61; P < ·01) and propensity score (HR, 9.71 per point increase; 95% CI, 4.04 -23.33; experienced these events were significantly less often treated with 18 months of TET plus HCQ, or TET plus QNL, or TET plus QNL plus HCQ (n = 3; 14%) compared to patients who did not experience these events (n = 75; 54%, P = .001). Total treatment duration was significantly longer in patients without PCR-positive relapse or chronic Q fever-related mortality after stop of treatment (median 101 weeks; interquartile range [IQR], 79-136) compared to patients with these events (median 71; IQR, 19-99, P = .02). Detailed clinical characteristics of patients who died of chronic Q fever-related causes or had PCR-positive relapse after stop of antibiotics are shown in Supplementary Table S1 .
DISCUSSION
Treatment of chronic Q fever with TET plus QNL was not inferior to treatment with TET plus HCQ in terms of all-cause mortality, chronic Q fever-related events, or therapy failure. Therefore, TET plus QNL seems to be a viable alternative for treatment with TET plus HCQ, for example, if the initial therapy cannot be tolerated due to side effects. This is in line with other studies that have shown that treatment with TET plus QNL is equally effective in terms of mortality [8, 9] . Treatment with TET plus QNL plus HCQ, TET monotherapy or QNL monotherapy were either associated with any of the outcomes. Since this was a retrospective study, treatment decisions were unstandardized. As a consequence, there is a substantial risk of confounding by indication. Theoretically, patients with more severe disease could be switched more often to combination therapy, leading to underestimation of the effect of these treatment strategies. Patients with mild disease are more likely to be switched to monotherapy, resulting in favorable outcome regardless of the treatment strategy. Treatment with TET or QNL monotherapy was not inferior to the reference treatment. However, conclusions should be drawn with caution. The fact that patients treated with QNL monotherapy (29%) or TET monotherapy (59%) were frequently switched to other therapies due to insufficient clinical response, which was subjectively interpreted by the treating clinician, emphasizes the importance of vigilant interpretation.
After stopping treatment, chronic Q fever-related mortality or PCR-positive relapses were observed in 13% of patients. These patients were significantly less often treated with (5) 5 (10) 3 (10) 3 (6) 9 (10) Decreased renal function
Other 35 (14) 9 (19) 9 (31) 2 (4) 11 (12) Reason for stop/switch
Side effects 110 (43) 13 (27) 12 (41) 7 (13) 25 (27) Deceased 30 (12) 5 (10) 3 (10) 3 (6) 11 (12) Adequate treatment finished 63 (25) 11 (22) 4 (14) 8 (15) 15 (16) Insufficient clinical response 31 (12) 8 (16) 3 (10) 32 (59) 27 (29) End of observation period (treatment unfinished) 29 (11) 5 (10) 8 (28) 4 (7) 19 (20) Other 38 (15) 10 (20) 1 (3) 8 (15) 11 (12) Abbreviations: HCQ, hydroxychloroquine; QNL, quinolone; TET, tetracycline. a Percentage of treated patients with proven or probable chronic Q fever, n = 276.
b Missing data in 9 patients.
c Missing data in 1 patient.
d Missing data in 3 patients.
e Missing data in 2 patients.
f One case of severe dehydration due to diarrhea induced by antibiotics, deceased due to heart failure after rehydration. Two cases of severe dehydration due to diarrhea with renal failure and consequential death.
18 months of appropriate antibiotics compared to patients who did not experience these events after stopping antibiotics, which underlines the importance of adequate treatment. In addition to treatment effectiveness, we described adverse drug reactions and reasons for switching. Patients switched frequently between treatment strategies. The proportion of patients who experienced side effects was high, especially for combination regimens. Correspondingly, combination regimens were most often discontinued due to side effects, which highlights the toxicity of these regimens.
The major strength of our study is the large number of patients studied. Chronic Q fever is rare and difficult to diagnose. To date, no more than 35 patients have been studied [6, 8, 9] . Furthermore, effectiveness of treatment in terms of complications has not been studied, making our study unique. Moreover, all chronic Q fever patients were diagnosed in a standardized way, and clinical data were well documented. Finally, median follow-up duration was almost 4 years, providing adequate follow-up. Hence, this well-documented study in this comprehensive cohort provides the best available evidence on treatment of chronic Q fever patients at this time. All patients diagnosed with chronic Q fever were included since we selected our patients based on microbiological results. Naturally, undiagnosed chronic Q fever patients and patients in noncollaborating hospitals were missed. Since the participation of hospitals in the endemic area is near 100%, we likely identified most Dutch chronic Q fever cases in the past 10 years.
The most important drawback of this study is its observational nature. To overcome the issues of a nonexperimental study, we used advanced methodological techniques, including different subsequent treatment strategies and a lag time of the effect. Despite these efforts, bias might still be present. Careful interpretation of the results is therefore essential. Moreover, we chose outcomes based on hard clinical endpoints but did not use serological course as an outcome measure. There is limited evidence to suggest that the course of phase I IgG titers predicts outcomes [23] . Furthermore, we did not account for progression of complications. Serological course and progression of complications detected using imaging studies could explain the proportion of patients who stopped QNL monotherapy due to insufficient clinical response, as judged by the clinician, without newly diagnosed complications or mortality. Another limitation is that data on occurrence of side effects were retrieved from patient records, potentially leading to underestimation Half weeks truncated to whole weeks.
Abbreviations: e.c.i., e cause ignota; HCQ, hydroxychloroquine; IQR, interquartile range; PCR, polymerase chain reaction; QNL, quinolone; TET, tetracycline. a Instead of median and IQR: minimum and maximum value since there are only 2 patients. of mild side effects due to underreporting. Finally, we did not model antibiotic dosage or compliance. Due to the complexity of the model, this would lead to uninterpretable results.
In conclusion, treatment of chronic Q fever with TET plus QNL appears to be a safe alternative, for example, if TET plus HCQ cannot be tolerated. Treatment with TET plus QNL plus HCQ was not superior to treatment with TET plus HCQ, although this may be caused by confounding by indication. Treatment with TET or QNL monotherapy should be avoided; switches due to subjective, insufficient clinical response were frequently observed.
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